Department of Thoracic Surgery, The First Affiliated Hospital of Gannan Medical University, Ganzhou, China.
Ganzhou Key Lab of Brain Injury & Brain Protection, Ganzhou, China.
Future Oncol. 2024;20(29):2213-2224. doi: 10.1080/14796694.2024.2376513. Epub 2024 Jul 29.
Lung cancer is one of the most common malignancies worldwide, with non-small cell lung cancer (NSCLC) being the most common type. As understanding of precise treatment options for NSCLC deepens, circulating tumor DNA (ctDNA) has emerged as a potential biomarker that has become a research hotspot and may represent a new approach for the individualized diagnosis and treatment of NSCLC. This article reviews the applications of ctDNA for the early screening of patients with NSCLC, guiding targeted therapy and immunotherapy, evaluating chemotherapy and postoperative efficacy, assessing prognosis and monitoring recurrence. With the in-depth study of the pathogenesis of NSCLC, plasma ctDNA may become an indispensable part of the precise treatment of NSCLC, which has great clinical application prospects.
肺癌是全球最常见的恶性肿瘤之一，其中非小细胞肺癌（NSCLC）最为常见。随着对 NSCLC 精确治疗方案的深入了解，循环肿瘤 DNA（ctDNA）作为一种潜在的生物标志物逐渐兴起，成为研究热点，可能为 NSCLC 的个体化诊断和治疗提供新途径。本文就 ctDNA 在 NSCLC 患者早期筛查、指导靶向治疗和免疫治疗、评估化疗和术后疗效、判断预后及监测复发中的应用进行综述。随着 NSCLC 发病机制的深入研究，血浆 ctDNA 可能成为 NSCLC 精准治疗不可或缺的一部分，具有广阔的临床应用前景。
